Mohammad Abdel‐Halim

1.2k total citations
82 papers, 895 citations indexed

About

Mohammad Abdel‐Halim is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Mohammad Abdel‐Halim has authored 82 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 23 papers in Organic Chemistry and 15 papers in Pharmacology. Recurrent topics in Mohammad Abdel‐Halim's work include Phosphodiesterase function and regulation (12 papers), Synthesis and biological activity (11 papers) and Cholinesterase and Neurodegenerative Diseases (10 papers). Mohammad Abdel‐Halim is often cited by papers focused on Phosphodiesterase function and regulation (12 papers), Synthesis and biological activity (11 papers) and Cholinesterase and Neurodegenerative Diseases (10 papers). Mohammad Abdel‐Halim collaborates with scholars based in Egypt, Germany and United States. Mohammad Abdel‐Halim's co-authors include Alireza Abadi, Matthias Engel, Ahmed K. ElHady, Samar Mansour, Rania M. Hathout, Gary A. Piazza, Heba Handoussa, Salma N. Tammam, Rasha M. El Nashar and Rolf W. Hartmann and has published in prestigious journals such as Scientific Reports, Food Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Mohammad Abdel‐Halim

77 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammad Abdel‐Halim Egypt 19 385 231 133 67 66 82 895
Silvio Aprile Italy 18 422 1.1× 549 2.4× 92 0.7× 108 1.6× 30 0.5× 50 1.0k
Song You China 17 653 1.7× 173 0.7× 82 0.6× 66 1.0× 43 0.7× 80 1.0k
Artur Beberok Poland 21 517 1.3× 147 0.6× 114 0.9× 146 2.2× 18 0.3× 78 1.4k
Neng Qiu China 18 267 0.7× 281 1.2× 61 0.5× 55 0.8× 32 0.5× 39 825
Chandrasekar Durairaj United States 20 464 1.2× 180 0.8× 87 0.7× 158 2.4× 103 1.6× 35 1.3k
Thikryat Neamatallah Saudi Arabia 18 301 0.8× 200 0.9× 73 0.5× 86 1.3× 9 0.1× 41 865
Kirti Patel India 21 353 0.9× 145 0.6× 167 1.3× 96 1.4× 13 0.2× 68 1.1k
Wenzhe Huang China 20 518 1.3× 80 0.3× 116 0.9× 60 0.9× 70 1.1× 102 1.2k
Jubie Selvaraj India 16 357 0.9× 421 1.8× 76 0.6× 123 1.8× 11 0.2× 104 1.0k

Countries citing papers authored by Mohammad Abdel‐Halim

Since Specialization
Citations

This map shows the geographic impact of Mohammad Abdel‐Halim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Abdel‐Halim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Abdel‐Halim more than expected).

Fields of papers citing papers by Mohammad Abdel‐Halim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Abdel‐Halim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Abdel‐Halim. The network helps show where Mohammad Abdel‐Halim may publish in the future.

Co-authorship network of co-authors of Mohammad Abdel‐Halim

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Abdel‐Halim. A scholar is included among the top collaborators of Mohammad Abdel‐Halim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Abdel‐Halim. Mohammad Abdel‐Halim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abdel‐Halim, Mohammad, Yi‐Hsuan Wang, Yu‐Cheng Chen, et al.. (2025). Targeting Neutrophil-Mediated Inflammation: Identification of Pyrazolidinone Carboxamide Derivatives as Potent Selective Inhibitors of Formyl Peptide Receptor 1 (FPR1)-Activated Neutrophils. ACS Pharmacology & Translational Science. 8(6). 1591–1609.
2.
Abdel‐Halim, Mohammad, et al.. (2024). Dual targeting of inflammation and β-cell dysfunction for therapy of diabetes mellitus. Journal of Drug Delivery Science and Technology. 97. 105718–105718.
3.
Chen, Po‐Jen, Yu‐Chieh Su, Ming‐Hua Shiao, et al.. (2024). N-Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents. Cancers. 16(11). 2033–2033. 2 indexed citations
4.
Haupenthal, Jörg, Jennifer Herrmann, Alireza Abadi, et al.. (2024). Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents. Archiv der Pharmazie. 357(4). e2300656–e2300656. 4 indexed citations
5.
Abadi, Alireza, et al.. (2024). N1‐Benzoylated 5‐(4‐pyridinyl)indazole‐based kinase inhibitors: Attaining haspin and Clk4 selectivity via modulation of the benzoyl substituents. Archiv der Pharmazie. 357(6). e2400020–e2400020. 3 indexed citations
6.
Gabr, Moustafa T., Leonardo Pisani, Daniela Valeria Miniero, et al.. (2024). Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity. European Journal of Medicinal Chemistry. 269. 116266–116266. 10 indexed citations
7.
Chen, Po‐Jen, et al.. (2024). Development of 5-hydroxybenzothiophene derivatives as multi-kinase inhibitors with potential anti-cancer activity. Future Medicinal Chemistry. 16(12). 1239–1254. 1 indexed citations
8.
Abutaleb, Nader S., Patrick D. Fischer, Christian Ducho, et al.. (2023). Discovery of 1,2-diaryl-3-oxopyrazolidin-4-carboxamides as a new class of MurA enzyme inhibitors and characterization of their antibacterial activity. European Journal of Medicinal Chemistry. 261. 115789–115789. 7 indexed citations
9.
ElHady, Ahmed K., et al.. (2023). Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives. Pharmaceuticals. 16(9). 1266–1266. 27 indexed citations
10.
11.
Abdel‐Halim, Mohammad, et al.. (2022). Molecularly Imprinted Solid Phase Extraction Strategy for Quinic Acid. Polymers. 14(16). 3339–3339. 3 indexed citations
12.
ElHady, Ahmed K., et al.. (2022). An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indications. Medicinal Research Reviews. 43(2). 343–398. 24 indexed citations
13.
Hamed, Mostafa M., Sotirios Katsamakas, Niki Vassilaki, et al.. (2022). Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors. Pharmaceuticals. 15(5). 632–632. 2 indexed citations
14.
Chen, Po‐Jen, Mostafa M. Hamed, Alireza Abadi, et al.. (2022). Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF-κB Inhibitors. Pharmaceuticals. 15(7). 778–778. 4 indexed citations
15.
Gabr, Moustafa T., Ahmed K. ElHady, Alireza Abadi, et al.. (2021). Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. ACS Chemical Neuroscience. 12(22). 4302–4318. 6 indexed citations
16.
Abdel‐Halim, Mohammad, Amr Hefnawy, Ahmed Maher, et al.. (2021). From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. Journal of Medicinal Chemistry. 64(8). 4462–4477. 19 indexed citations
17.
Abdel‐Halim, Mohammad, et al.. (2021). Taurine loaded chitosan-pectin nanoparticle shows curative effect against acetic acid-induced colitis in rats. Chemico-Biological Interactions. 351. 109715–109715. 27 indexed citations
18.
Vassilaki, Niki, et al.. (2019). Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds. ACS Omega. 4(7). 11440–11454. 5 indexed citations
19.
Abdel‐Halim, Mohammad, Kevin Lee, Gary A. Piazza, et al.. (2018). Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors. Archiv der Pharmazie. 351(5). e1800018–e1800018. 15 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvio Aprile Breakdown of academic impact, for papers by Song You Breakdown of academic impact, for papers by Artur Beberok Breakdown of academic impact, for papers by Neng Qiu Breakdown of academic impact, for papers by Chandrasekar Durairaj Breakdown of academic impact, for papers by Thikryat Neamatallah Breakdown of academic impact, for papers by Kirti Patel Breakdown of academic impact, for papers by Wenzhe Huang Breakdown of academic impact, for papers by Jubie Selvaraj
Rankless by CCL
2026